St. Joseph Cancer Center - Clinical Trials: Genitourinary
 

Prostate:

  • CTSU C90202: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone.
  • CTSU C90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
  • SWOG 0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate
  • SWOG 0354: A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer

Bladder:

  • SWOG 0353: Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG

Renal Cell:

  • CTSU E2805: A Randomized Phase III Trail of Adjuvant SU011248 (Suitinib), BAY 43- 9006 (Sorafinib) vs Placebo in Patients with Resected Renal Cell Carcinoma.

 

For more information on the above clinical trials: Cheryl Patz, RN, OCN, CCRC, 360.715.4133

 

Return to previous page

Cancer Services